News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
11,026 Results
Type
Article (357)
Press Release (10669)
Section
Business (2614)
Deals (452)
Drug Delivery (1)
Drug Development (2499)
FDA (411)
Job Trends (372)
News (5874)
Policy (464)
Tag
Academia (27)
Accelerated approval (1)
Allergies (8)
Alliances (557)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (18)
Approvals (438)
Artificial intelligence (5)
Autoimmune disease (6)
Automation (1)
Bankruptcy (3)
Best Places to Work (383)
Biosimilars (4)
Bladder cancer (21)
Breast cancer (13)
Cancer (146)
Cardiovascular disease (9)
Cell therapy (10)
Cervical cancer (3)
Clinical research (2408)
Collaboration (33)
Compensation (26)
Complete response letters (2)
COVID-19 (9)
CRISPR (1)
C-suite (19)
Cystic fibrosis (1)
Data (296)
Depression (1)
Dermatology (4)
Diabetes (18)
Diagnostics (37)
Drug discovery (3)
Drug pricing (1)
Duchenne muscular dystrophy (9)
Earnings (1278)
Events (1803)
Executive appointments (20)
FDA (525)
Funding (22)
Gene editing (3)
Gene therapy (38)
GLP-1 (10)
Government (56)
Grass and pollen (1)
Guidances (7)
Healthcare (270)
IgA nephropathy (3)
Immunology and inflammation (11)
Indications (8)
Infectious disease (11)
Influenza (1)
Intellectual property (3)
IPO (262)
Job creations (20)
Layoffs (7)
Legal (34)
Liver cancer (5)
Longevity (1)
Lung cancer (34)
Lymphoma (3)
Manufacturing (8)
MASH (1)
Medical device (178)
Medtech (178)
Mergers & acquisitions (223)
Metabolic disorders (27)
Multiple sclerosis (3)
Neurodegenerative disease (1)
Neuropsychiatric disorders (1)
Neuroscience (21)
NextGen: Class of 2026 (55)
Non-profit (16)
Now hiring (1)
Obesity (6)
Ovarian cancer (16)
Pain (22)
Patents (7)
Patient recruitment (22)
People (857)
Phase 1 (553)
Phase 2 (1053)
Phase 3 (1029)
Pipeline (222)
Policy (1)
Postmarket research (60)
Preclinical (200)
Prostate cancer (1)
Radiopharmaceuticals (4)
Rare diseases (19)
Real estate (22)
Regulatory (529)
Reports (1)
Research institute (21)
Series A (1)
Series B (6)
Sickle cell disease (1)
Startups (61)
Supply chain (1)
The Weekly (1)
Vaccines (8)
Venture capital (1)
Weight loss (1)
Date
Today (10)
Last 7 days (24)
Last 30 days (65)
Last 365 days (664)
2026 (226)
2025 (684)
2024 (853)
2023 (974)
2022 (1129)
2021 (1264)
2020 (941)
2019 (686)
2018 (516)
2017 (557)
2016 (497)
2015 (586)
2014 (379)
2013 (223)
2012 (204)
2011 (221)
2010 (238)
Location
Africa (2)
Arizona (4)
Asia (553)
Australia (79)
California (251)
Canada (41)
China (26)
Colorado (1)
Connecticut (3)
Delaware (23)
Europe (1479)
Florida (23)
Georgia (23)
Idaho (5)
Illinois (15)
India (5)
Indiana (7)
Japan (24)
Kentucky (1)
Maryland (20)
Massachusetts (297)
Michigan (7)
Minnesota (4)
New Jersey (103)
New York (86)
North Carolina (48)
Northern California (126)
Ohio (8)
Pennsylvania (62)
Rhode Island (1)
South America (6)
Southern California (101)
Tennessee (17)
Texas (24)
United States (1027)
Virginia (1)
Washington State (16)
11,026 Results for "ocular therapeutix".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
April 27, 2026
·
3 min read
Press Releases
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
April 22, 2026
·
2 min read
Press Releases
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
April 28, 2026
·
2 min read
Mergers & acquisitions
Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring
Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is underway, with data expected this quarter.
January 16, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
April 29, 2026
·
9 min read
Press Releases
Ocular Therapeutix™ to Participate in March 2026 Investor Conferences
February 24, 2026
·
2 min read
Press Releases
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
April 1, 2026
·
3 min read
Press Releases
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2026
April 14, 2026
·
3 min read
Press Releases
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
April 13, 2026
·
15 min read
Press Releases
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 9, 2026
March 9, 2026
·
2 min read
1 of 1,103
Next
